CD274 and neoplasm: Recently, it has been revealed that TNBC is the immune-modulatory subtype as TNBC is more likely to show increased expression of PD-L1 in the tumor microenvironment, and the presence of tumor infiltrating lymphocytes (TILs) has shown a clear association with clinical outcomes and improved survival [38,39,40].